John’s intellectual property legal practice included clients in the pharmaceutical, biotechnology, and medical equipment industries. He represented companies and private equity firms in building and assessing patent portfolios to support company funding in capital markets. He also represented early stage, middle market, and large companies in proactively employing their intellectual property for strategic advantage in the marketplace. He rendered patentability, validity, and infringement opinions and was engaged in patent prosecution and due diligence matters. John also advised pharmaceutical, biotechnology, medical device and food manufacturers in representations before the Food and Drug Administration. These included advice on new drug applications, investigational new drug applications abbreviated new drug applications, clinical trials, current good manufacturing practices, labelling requirements, and pre-market notifications and applications.
Biotechnology and Pharmaceuticals
